Publication List

ORIGINAL PUBLICATIONS (Peer review)

1. Geiser M, **Serra AL**, Cruz-Orive LM, Baumann M, Im Hof V, Gehr P. Efficiency of airway macrophage recovery by bronchoalveolar lavage in hamsters: a stereological approach. Eur Respir J. 1995 Oct;8(10):1712-8.
2. Vogt B, Ferrari P, Schonholzer C, Marti HP, Mohaupt M, Wiederkehr M, Cereghetti C, **Serra A**, Huynh-Do U, Uehlinger D, Frey FJ. Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. Am J Med. 2001 Dec 15;111(9):692-8.
3. **Serra A**, Uehlinger DE, Ferrari P, Dick B, Frey BM, Frey FJ, Vogt B. Glycyrrhetinic acid decreases plasma potassium concentrations in patients with anuria. J Am Soc Nephrol. 2002 Jan;13(1):191-6.
4. Heiniger CD, Kostadinova RM, Rochat MK, **Serra A**, Ferrari P, Dick B, Frey BM, Frey FJ. Hypoxia causes down-regulation of 11 beta-hydroxysteroid dehydrogenase type 2 by induction of Egr-1. FASEB J. 2003 May;17(8):917-9.
5. Yu Z[†]; **Serra A[†]**; Sauter D; Loffing J; Ackermann D; Frey F, Frey B; Vogt B. Sodium retention in rats with liver cirrhosis is associated with increased renal abundance of NaCl cotransporter (NCC). Nephrol Dial Transplant. 2005 Sep;20(9):1833-41. [†] contributed equally.
6. **Serra AL**, Schwarz AA, Wick FH, Marti HP, Wüthrich RP. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005 Jul;20(7):1315-9.
7. Wahl PR, **Serra A**L, Le Hir M, Molle KD, Hall MN, Wüthrich RP. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).Nephrol Dial Transplant. 2006 Mar;21(3):598-604.
8. **Serra AL**, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, Wüthrich RP. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007 Feb;22(2):577-83.
9. Rippin S, **Serra AL**, Marti HP and Wüthrich RP. Six-year follow up of azathioprine and mycophenolate mofetil use during the first 6 months of renal transplantation. Clin Nephrol. 2007 Jun;67(6):374-80.
10. Wahl PR, Le Hir M, Vogetseder A, Arcaro A, Starke A, Waeckerle-Men Y, **Serra AL,** Wüthrich RP. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology. 2007 Aug;12(4):357-63.
11. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, **Serra AL**. Inhibition of the mTOR signaling pathway with everolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease Kidney Blood Press Res. 2007 Jun 27;30(4):253-259.
12. Corsenca A, Moch, M, Weber M, Wüthrich RP, **Serra AL**. Combined nephrectomy and preemptive renal transplantation in a patient with tuberous sclerosis complex. Nephrol Dial Transplant. 2007 22(11):3330-3.
13. **Serra AL**, Kistler A, Poster D, Struker M, Wüthrich RP, Weishaupt D, Tschirch F. Study protocol of a proof-of-concept trial to assess the therapeutic effect of the mammalian target of rapamycin inhibitor sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study [NCT00346918]. BMC Nephrology 2007 Sep 15;8(1):13.
14. Berthier CC, Wahl PR, Le Hir M, Marti HP, Wagner U, Rehrauer H, Wüthrich RP, **Serra AL**. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of ADPKD. Nephrol Dial Transplant. 2008 Mar;23(3):880-9.
15. **Serra AL**, SC Braun, A Starke, R Savoca, M Hersberger, S Russmann, N Corti and RP Wüthrich. Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation. Am J Transplant. 2008 Apr;8(4):803-10.
16. **Serra AL**, Wuhrmann C, Wüthrich RP. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism. Am J Kidney Dis. 2008 52(6):1151-7.
17. Hofbauer GFL, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, **Serra AL.** The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a tuberous sclerosis patient. Br J Dermatol. 2008 Aug;159(2):473-5.
18. Grimmelt A, Cohen CD, Fehr T, **Serra AL** and Wüthrich RP. Safety and tolerability of ferric carboxymaltose (FCM) for treatment of iron deficiency in patients with chronic kidney disease and in kidney transplant recipients. Clin Nephrol. 2009;71(2):125-9.

19. Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, Binet I, Spanaus K, Wüthrich RP and **Serra AL**. Increases in kidney volume in Autosomal Dominant Polycystic Kidney Disease can be detected within 6 months, Kidney Int. 2009 Jan;75(2):235-41.
20. Poster D, Kistler AD, Krauer F, Blumenfeld JD, Rennert H, Weishaupt D, Wüthrich RP and **Serra AL**. Kidney function and volume progression in unilateral ADPKD with contralateral renal agenesis or hypoplasia: a case series. Am J Kidney Dis. 2009 Sep;54(3):450-8.
21. Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP and **Serra AL**. Identification of a unique urinary biomarker profile in autosomal dominant polycystic kidney disease. Kidney Int. 2009 Jul;76(1):89-96.
22. Etter Ch, Russi R, Fogazzi GB, Wüthrich RP, **Serra AL**. Maltese cross-like crystals in the urinary sediment of a diabetic patient. NDT Plus 2009; 2:405-407
23. **Serra AL**, Kistler AD, Poster D, Krauer F, Senn O, Raina S, Pavik I, Rentsch K, Regeniter A, Weishaupt D, Wüthrich RP. Safety and tolerability of sirolimus treatment in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. Nephrol Dial Transplant. 2009 Nov;24(11):3334-42.
24. Kistler AD, Poster D, Wüthrich RP, **Serra AL**. Hydronephrosis in autosomal dominant polycystic kidney disease. Kidney Int. 2009 Dec;76(12):1297.
25. Wu M, Arcaro A, Varga Z, Vogetseder A, Le Hir M, Wüthrich RP, **Serra AL**. Pulse mTOR inhibitor treatment effectively controls cyst growth but leads to severe parenchymal and glomerular hypertrophy in rat polycystic kidney disease. Am J Physiol Renal Physiol. Am J Physiol Renal Physiol. 2009 Dec;297(6):F1597-605..

REVIEWS

1. **Serra A,** Wüthrich RP. Klassifikationen und Therapieoptionen bei chronischer Niereninsuffizienz. CardioVasc. 2005 8-13
2. **Serra A**, Wüthrich RP. Wie kann die Gefässkalzifikation gestoppt warden? CardioVasc. 2006 12-17.
3. Wüthrich RP, **Serra A**. The red urine. Ther Umsch. 2006; 63:595-600.
4. **Serra AL**, Wüthrich RP. Therapie des persistierenden Hyperparathyreoidismus nach Nierentransplantation. Nephrologie im Dialog. 2007; 1:8-12.
5. **Serra AL**, Wüthrich RP. Weiterbildung - zertifizierte Fortbildung. Autosomal-dominante polyzystische Nierenerkrankung. Der Nephrologe. 2007; 6:459-466.
6. **Serra AL**, Wüthrich RP. Polyzystische Nierenerkrankung: wenn Zysten die Niere zerstören. Ärztliche Praxis Urologie 2008; 1:18-21
7. **Serra AL**, Wüthrich RP: Use of cinacalcet to control hyperparathyroidism. Review of endocrinology, 2008; 2:41-45.
8. Hofbauer GFL, Marcollo-Pini A, French LE, Wüthrich RP, **Serra AL**. mTOR Inhibitoren bremsen gutartige und bösartige vaskuläre Proliferation am Beispiel von Kaposisarkom und Angiofibrom bei tuberöser Sklerose. Derm. Helv. 2009; 1:17-18
9. Wüthrich RP, **Serra AL**. Mammalian target of rapamycin and autosomal dominant polycystic kidney disease. Transplant Proc. 2009 Jul-Aug;41(6 Suppl)
10. Wüthrich RP, **Serra AL**, Kistler AD. Autosomal Dominant Polycystic Kidney Disease: New Treatment Options and How to Test Their Efficacy. Kidney Blood Press Res. 2009 Nov 3;32(5):380-387.
11. Hofbauer GF, Anliker M, Arnold A, Binet I, Hunger R, Kempf W, Laffitte E, Lapointe AC, Pascual M, Pelloni F, **Serra A**; Swiss clinical practice guidelines for skin cancer in organ transplant recipients. SGDV working group for organ transplant recipients. Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15.
12. **Serra A**L, Wüthrich RP. Autosomal dominante polyzystische Nierenerkrankung (ADPKD). Pathogenese, Klinik und neue Therapieansätze. Schweiz Med Forum 2009;9(47):854-858.
13. **Serra AL**, Wüthrich RP. Rapamycin: eine neue Therapieoption bei autosomal dominanter polyzystischer Nierenerkrankung (ADPKD)? Praxis (Bern 1994). 2009 Dec 16;98(25):1511-6.

Zürich, February 20th, 2010

Place, Date

PD Dr. Andreas Serra